Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
BIORA THERAPEUTICS, INC. (PROG) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Investor presentation, Quarterly results
Docs: "Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results NaviCapTM targeted oral delivery platform on track for September IND filing; achieved successful device function study results in humans with phase 1-ready device BioJetTM systemic oral delivery platform device development achieved function targets while continuing to exceed bioavailability targets The company strengthened its intellectual property position with additional patents for both platforms Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific",
"THERAPEUTIC PIPELINE PROGRAM PROGRAM INDICATION DESIGN/FEASIBILITY PRECLINICAL CLINICAL TARGETED THERAPEUTICS"
11/14/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/28/2022 8-K Investor presentation, Quarterly results
Docs: "Progenity Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results Accelerated Company Transformation Toward Oral Delivery of Biotherapeutics and Targeted Therapeutics Programs Progressed Company’s Targeted Therapeutics Clinical Programs with Initiation of Clinical Device Performance Study in Patients with Ulcerative Colitis Management will host conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific",
"TARGETED THERAPEUTICS SYSTEMIC THERAPEUTICS PGN-001"
11/10/2021 8-K Investor presentation, Quarterly results
Docs: "Progenity Provides Corporate Update and Reports Third Quarter 2021 Financial Results Added important patents further protecting the company’s therapeutic delivery technologies Added strong biotherapeutics capabilities to management team and board of directors Implemented cost-cutting measures expected to result in approximately $145 million in cost savings on an annual basis1 Management will host conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific",
"ORAL DELIVERY OF BIOTHERAPEUTICS GI-TARGETED THERAPEUTICS ODBS"
08/12/2021 8-K Investor presentation, Quarterly results
Docs: "Progenity, Inc. Condensed Consolidated Statements of Operations Three Months Ended June 30, 2021 Revenues $ 463 $ 167 Cost of sales — — Gross profit 463 167 Operating expenses: Research and development 13,401 11,673 Selling and marketing 2,006 1,858 General and administrative 20,709 18,100 Total operating expenses 36,116 31,631 Loss from operations Interest expense gain on warrant liability 2,650 Interest and other income, net 2,901 14,873 Loss from continuing operations Loss from discontinued operations Net loss $ $ Net loss per share from continuing operations, basic and diluted $ $ Net loss per share from discontinued operations, basic and diluted $ $ Net loss per share, basic and diluted $ $ Weighted average number of shares outstanding used in calculating net loss per share, basi...",
"S HEALTH STRATEGIC TRANSFORMATION ORAL BIOTHERAPEUTICS GASTROINTESTINAL HEALTH"
03/18/2021 8-K Investor presentation, Quarterly results
Docs: "Pressrelease",
"Earnings presentation"
08/13/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy